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Abstract
The transfection of human cells with siRNA against adapter-related protein complex 2 alpha 1 subunit (AP2α) was revealed to significantly up-
regulate the replication of human immunodeficiency virus type 1 (HIV-1). This effect was confirmed by cell infection with vesicular stomatitis
virus G protein-pseudotyped HIV-1 as well as CXCR4-tropic and CCR5-tropic HIV-1. Viral adsorption, viral entry and reverse transcription
processes were not affected by cell transfection with siRNA against AP2α. In contrast, viral nuclear translocation as well as the integration process
was significantly up-regulated in cells transfected with siRNA against AP2α. Confocal fluorescence microscopy revealed that a subpopulation of
AP2α was not only localized in the cytoplasm but was also partly co-localized with lamin B, importin β and Nup153, implying that AP2α
negatively regulates HIV-1 replication in the process of nuclear translocation of viral DNA in the cytoplasm or the perinuclear region. We propose
that AP2α may be a novel target for disrupting HIV-1 replication in the early stage of the viral life cycle.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV-1; AIDS; RNA interference; siRNA; Host factor; AP-2; Adapter-related protein complex 2 alpha 1 subunit; Nuclear translocation; IntegrationIntroduction
Human immunodeficiency virus type 1 (HIV-1) is a cau-
sative agent of acquired immune deficiency syndrome (AIDS).
HIV-1 replication is governed by a complex regulatory mech-
anism, and many host factors are involved either positively or
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doi:10.1016/j.virol.2007.11.033et al., 2005). Some such host factors were found to be deter-
minants of cell tropism and/or the host range of HIV-1 (Cullen,
2003; Deng et al., 1996; Dragic et al., 1996; Feng et al., 1996;
Sokolskaja and Luban, 2006; Stremlau et al., 2004; Wei et al.,
1998; Zheng et al., 2003). Although many host factors have
already been identified, the regulatory mechanism of the HIV-1
life cycle is still not fully understood.
RNA interference (RNAi) has been found as a highly ef-
fective and widely used methodology for the suppression of
specific gene expression in eukaryotic cells. Small interfering
RNA (siRNA), comprised of a duplex of two 21-mer RNAs with
19 complimentary nucleotides and 3′ terminal 2 non-comple-
mentary nucleotides, can induce the RNAi-mediated specific
suppression of target genes in eukaryotic cells (Elbashir et al.,
Fig. 1. siRNA against AP2α, but not against clathrin, significantly enhances
HIV-1 replication in the early stage of the viral life cycle. (A) Schematic illu-
stration of the target position of three siRNAs in the open reading frame (orf) of
AP2α gene. (B) J111 (left upper and lower panels) or MAGIC5A cells (right
upper and lower panels) were transfected with AP2α siRNA1 (AP2α-1: solid
bar), AP2α siRNA2 (AP2α-2: left hatched bar), AP2α siRNA3 (AP2α-3: right
hatched bar), clathrin siRNA (clathrin: dark gray bar), control (non-silencing)
siRNA (Control-1: open bar) or FLJ10847 siRNA (Control-2: light gray bars),
as indicated. Forty-eight hours after transfection, the cells were infected with
HIV-1/VSVG, HIV-1/X4 or HIV-1/R5, as indicated below the panels. Twenty-
four hours after infection, luciferase activity in infected cells was measured.
Data are shown as fold induction relative to luciferase activity in cells trans-
fected with control siRNA. Data are presented as the means and standard
deviations (error bars) of more than three independent experiments.
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replication, we previously studied the level of HIV-1 replication
in cells transfected with a series of siRNAs directed against
cellular genes selected as functional molecules to be involved in
intracellular signal transduction pathways, intracellular trans-
portation processes and the cytoskeletal system (siRNA mini-
library) (Kameoka et al., 2007; Ui-Tei et al., 2004). We found
that the levels of the single replication cycle of luciferase reporter
HIV-1 were significantly enhanced in cells transfected with
siRNAs against adapter-related protein complex 2 (AP-2) alpha
1 subunit (AP2α), ADP-ribosylation factor 6, Axin1, dual spe-
cificity phosphatase 1, Janus kinase 1 and partitioning defec-
tive 6 homolog alpha (Kameoka et al., 2007), suggesting that
those cellular proteins may negatively regulate HIV-1 replica-
tion under normal cell culture conditions. Among them, siRNA
against AP2αmost effectively enhanced HIV-1 replication (Ka-
meoka et al., 2007).
AP2α is a major component of AP-2 that is known to re-
gulate receptor-mediated, clathrin-dependent endocytosis of
plasma membrane proteins (Connor and Schmid, 2003; Nakatsu
and Ohno, 2003; Robinson, 2004). Several reports suggest that
AP-2 plays roles in HIV-1 replication (Batonick et al., 2005;
Boge et al., 1998; Daecke et al., 2005). AP-2 was shown to play
negative roles in the late phase of the viral life cycle (Batonick
et al., 2005; Boge et al., 1998), while it was also shown to play a
role in alternative, endocytosis-mediated HIV-1 entry into cells
(Daecke et al., 2005). In this study, we show that siRNA against
AP2α enhanced the level of nuclear viral DNA as well as of
integrated proviral DNA, while viral adsorption, viral entry and
reverse transcription (RT) processes were not notably affected
by siRNA against AP2α. These results suggest that AP2α plays
a role(s) in HIV-1 replication in the process of nuclear trans-
location of viral DNA, but not in earlier process such as viral
entry in the plasma membrane. We also revealed that a sub-
population of AP2α was not only localized in the cytoplasm,
but also partly co-localized with proteins functioning in the
perinuclear region, implying that AP2α may play a negative
role in HIV-1 replication in the cytoplasm or the perinuclear
region.
Results
siRNA directed against AP2α significantly enhances HIV-1
replication
Previously, we studied the replication level of vesicular sto-
matitis virus G protein (VSVG)-pseudotyped, luciferase reporter
HIV-1 (HIV-1/VSVG) in J111 cells transfected with a series of
siRNAs directed against cellular genes (siRNA mini-library).
Among 257 siRNAs, siRNA directed against AP2α most sig-
nificantly enhanced the level of a single replication cycle of
luciferase reporter HIV-1 (Kameoka et al., 2007). In this report,
we further studied the regulatory mechanism of AP2α in HIV-1
replication. First, we verified the results of screening tests using
the siRNA against AP2α (AP2α siRNA1) that was equivalent to
the one included in siRNA mini-library. J111 cells were trans-
fected with AP2α siRNA1 or control siRNAs. The cells werethen infected with HIV-1/VSVG. In addition, we examined
the replication of CXCR4-tropic (X4) HIV-1 (HIV-1/X4) and
CCR5-tropic (R5) HIV-1 (HIV-1/R5), as well as of HIV-1/
VSVG, in MAGIC5A cells transfected with AP2α siRNA1.
Using these reporter viruses bearing the luciferase gene in place
of the viral nef gene, the efficiency of the early phase of the HIV-
1 replication cycle, including viral entry, RT, nuclear transloca-
tion, integration, RNA transcription and protein translation,
could be monitored by measuring luciferase activity in infected
cells (Chen et al., 1994; Connor et al., 1995). The results showed
that the replication of HIV-1/VSVG (Fig. 1B, left and right upper
panels), as well as HIV-1/X4 and HIV-1/R5 (Fig. 1B, right upper
panel), was strongly up-regulated by cell transfection with AP2α
siRNA1. The replication of three reporter viruses which enter
cells by means of interaction with different transmembrane mo-
lecules seemed to be likewise enhanced by cell transfection with
Fig. 2. siRNAs against AP2α and clathrin specifically suppressed the expression
of their target gene products. J111 and MAGIC5A cells, as indicated beside the
panels, were transfected with indicated siRNA. Forty-eight hours after trans-
fection, the cell lysate was prepared and subjected to immunoblot analysis using
anti-AP2α (A), clathrin (B) or α-tubulin (A and B) antibodies, as described in
Materials and methods.
Fig. 3. siRNA against AP2α does not affect viral adsorption or viral entry into
cells. J111 (left panels) or MAGIC5A cells (right panels) were transfected with
AP2α siRNA1 (AP2α-1: solid bar), control (non-silencing) siRNA (Control-1:
open bar) or FLJ10847 siRNA (Control-2: light gray bar). Forty-eight hours
after transfection, the cells were infected with HIV-1/VSVG, HIV-1/X4 or HIV-
1/R5, as indicated below the panels. The levels of viral adsorption and viral entry
were examined, as described in Materials and methods. As control experiments,
cells were incubated with Env-deficient viral particles, and the levels of Env-
independent, non-specific adsorption and viral entry were estimated. The
relative amounts of Env-dependent viral adsorption (A) and viral entry (B) were
then calculated by subtracting the amounts of such non-specific viral adsorption
and entry. Data are presented as the means and standard deviations (error bars) of
three independent experiments.
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gative role in HIV-1 replication after the entry process of the viral
life cycle under normal cell culture conditions. To confirm the
specific RNAi effect of siRNA on AP2α gene expression, we
tested three siRNAs targeting different position in the AP2α
gene (Fig. 1A). The results showed that three siRNAs against
AP2α exhibited similar tendencies of the enhancing effect on
HIV-1/VSVG replication (Fig. 1B, left upper and lower panels)
and of the suppressing effect on AP2α expression (Fig. 2A).
Among three siRNAs against AP2α, AP2α siRNA1 was most
effective on AP2α expression (Fig. 2A) as well as on HIV-1
replication (Fig. 1B, compare left upper and lower panels).
AP2α siRNA1 was designed as highly effective and specific
siRNA based on the novel technique described previously (Ui-
Tei et al., 2004), and therefore AP2α siRNA1 might be more
effective compared with AP2α siRNA2 or 3. We used AP2α
siRNA1 for the subsequent experiments described below.
Clathrin-dependent endocytosis is not involved in AP2α
siRNA-induced up-regulation of HIV-1 replication
AP2α is a major subunit of AP-2 (Nakatsu and Ohno, 2003).
Since AP-2 is known to play a role in the clathrin-dependent
endocytosis mechanism, this type of endocytosis is possibly
involved in the AP2α siRNA-induced up-regulation of HIV-1
replication observed. To examine this possibility, we studied the
replication of HIV-1/X4 and HIV-1/R5 in MAGIC5A cells
transfected with siRNA directed against clathrin. The siRNA
against clathrin, which inhibits clathrin-dependent endocytosis
(Motley et al., 2003), effectively suppressed clathrin expression
(Fig. 2B) and HIV-1 Nef-dependent CD4 down-regulation
(Supplementary Fig. S1), whereas the siRNA against AP2α
weakly suppressed Nef-dependent CD4 down-regulation (Sup-
plementary Fig. S1), consistently with a previous report (Chaud-
huri et al., 2007). The results showed that the level of replication
of HIV-1/X4 in clathrin siRNA-transfected cells was comparableto that in cells transfected with control siRNAs (Fig. 1B, right
lower panel). In addition, the replication of HIV-1/R5 was rather
suppressed by transfecting cells with siRNA against clathrin
(Fig. 1B, right lower panel). Namely, the suppression of clathrin-
dependent endocytosis does not enhance HIV-1 replication.
Based on these results, we can conclude that siRNAs against
AP2α enhance HIV-1 replication independently of the clathrin-
dependent endocytosis mechanism.
siRNA against AP2α does not affect viral adsorption and viral
entry processes of HIV-1 replication
We next studied the levels of viral adsorption and viral entry
processes of HIV-1 by measuring the amount of p24 antigen that
binds to and penetrates into cells, respectively. Cells were trans-
fected with siRNA against AP2α and then infected with HIV-1.
After the washing process, cell lysates were prepared and the
amount of p24 antigen in the samples was measured. The results
showed that the levels of viral adsorption (Fig. 3A, left panel) and
viral entry (Fig. 3B, left panel) of HIV-1/VSVGwere comparable
among cells transfected with siRNA against AP2α or control
siRNAs. In addition, the levels of viral adsorption (Fig. 3A, right
panel) and viral entry (Fig. 3B, right panel) of HIV-1/X4 andHIV-
1/R5 were rather slightly decreased in AP2α siRNA-transfected
Fig. 4. HIV-1 RT process is not affected by cell transfection with siRNA against
AP2α. J111 cells were transfected with AP2α siRNA1 (AP2α-1: solid circle) or
control (non-silencing) siRNA (open circle). Forty-eight hours after transfection,
the cells were infected with DNase I-treated HIV-1/VSVG (40 ng of p24).
Cellular DNAwas extracted at 3, 6, 12 and 24 h after infection, and subjected to
real-time PCR using the primers/probe sets for detecting early (A) or late (B) RT
products. The copy number of HIV-1 DNA per cell was calculated as described
in Materials and methods. Data are presented as the means and standard
deviations (error bars) of more than three independent experiments.
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not up-regulate viral adsorption and viral entry processes, sug-
gesting that siRNA against AP2αmay enhance HIV-1 replication
after the viral entry process of the viral life cycle.
siRNA against AP2α does not affect the RT process of HIV-1
replication
To study the effect of AP2α siRNA on RT process of HIV-1,
we performed semi-quantitative analysis of viral DNA in infectedFig. 5. Viral nuclear translocation as well as viral integration is enhanced by cell
transfection with siRNA against AP2α. J111 cells were transfected with AP2α
siRNA1 (AP2α-1: solid circle) or control (non-silencing) siRNA (open circle).
Forty-eight hours after transfection, the cells were infected with DNase I-treated
HIV-1/VSVG (40 ng of p24). Then, Cellular DNA was extracted at 6, 12 and
24 h after infection. Real-time PCR for detecting the 2-LTR circular form of
HIV-1 DNA (A) or integrated HIV-1 DNA (B) was performed. The relative
amounts of 2-LTR circular form of HIV-1 DNA (A) and integrated proviral
DNA (B) were estimated as described in Materials and methods. Data are
presented as the means and standard deviations (error bars) of three independent
experiments.cells using real-time PCR. J111 cells were transfectedwith siRNA
and then infected with HIV-1/VSVG. Cellular DNA was then
extracted at various times after infection, and we performed real-
time PCR to detect early (Fig. 4A) and late (Fig. 4B) products of
the viral RT process. The results showed that the kinetics for the
reverse transcribed viral DNA production were comparable be-
tween cells transfected with siRNA against AP2α and with
control siRNA (Fig. 4). The production of viral DNA reached
maximum levels at about 6 h after infection and declined there-
after (Fig. 4), indicating that the unintegrated HIV-1 DNA was
probably rapidly degraded by cellular nucleases and/or was
diluted by growth of cells. In addition, we also examined the viral
DNA production in MAGIC5A cells infected with HIV-1/X4
or HIV-1/R5. The results showed that the kinetics for the viral
DNA production were comparable between cells transfected with
siRNA against AP2α and with control siRNA (Supplementary
Fig. S2). These results suggest that the transfection of cells with
siRNA against AP2α does not affect the HIV-1 RT process.
The level of nuclear viral DNA as well as integrated proviral
DNA is increased in cells transfected with siRNA against AP2α
Next, we studied the nuclear translocation of HIV-1 by mea-
suring the level of the 2-LTR circular form of viral DNA using
inverted real-time PCR (Cara et al., 2002; Chang et al., 2005).
The results showed that the level of the 2-LTR circular form of
HIV-1 DNA was markedly increased at 24 h after infection in
cells transfected with siRNA against AP2α compared with con-
trol cells (Fig. 5A). In addition, we performed Alu real-time PCR
(Bulter et al., 2001; Kameoka et al., 2005) to estimate the level of
integrated proviral DNA. The results showed that the level of
proviral DNA was significantly increased in cells transfected
with siRNA against AP2α compared with control cells (Fig. 5B).Fig. 6. Interaction between AP-2 and HIV-1 Gag is dispensable for the
regulatory function of AP2α in HIV-1 replication in the early phase of the viral
life cycle. (A) J111 cells were infected with 40 ng (p24) of HIV-1/VSVG (open
bar) or HIV-1gagV135A/VSVG (right hatched bar). Twenty-four hours after
infection, luciferase activity in infected cells was measured. (B) J111 cells were
transfected with AP2α siRNA1 (AP2α-1: solid bar), control (non-silencing)
siRNA (Control-1: open bar) or FLJ10847 siRNA (Control-2: light gray bar).
Forty-eight hours after transfection, cells were infected with 40 ng (p24) of HIV-
1/VSVG or HIV-1gagV135A/VSVG, as indicated below the panel. Twenty-
four hours after infection, luciferase activity in infected cells was measured.
Data are shown as fold induction relative to luciferase activity in cells
transfected with control siRNA. Data are presented as the means and standard
deviations (error bars) of three independent experiments.
Fig. 7. A subpopulation of AP2α is not only localized in cytoplasm, but also partly co-localized with proteins functioning in the perinuclear region. Permeabilized J111
cells were immunostained using an antibody for AP2α together with those for lamin B (A–D), importin α (E–H), importin β (I–L) or Nup153 (M–P), and
fluorescence images were examined by confocal fluorescence microscopy, as described in Materials and methods. Fluorescence images of AP2α (green; A, E, I and
M), lamin B (red, B), importin α (red, F), importin β (red, J) and Nup153 (red, N), merged images (C, G, K and O) as well as enlarged areas of merged images (D, H, L
and P) are shown. Arrows indicate merged (yellow) signals. Similar images were observed for more than twenty independent experiments.
175Y. Kitagawa et al. / Virology 373 (2008) 171–180These results suggest that siRNA against AP2α up-regulates
HIV-1 replication in the process of nuclear translocation of viral
DNA, and thus, eventually the level of integrated proviral DNA
is also increased in cells transfected with siRNA against AP2α.
Interaction between HIV-1 Gag and AP-2 is dispensable for the
regulation of HIV-1 replication in the early stage of the viral
life cycle by AP2α
AP-2 is reported to play a role in the late phase of the viral life
cycle (Batonick et al., 2005; Boge et al., 1998) and also to
interact with HIV-1 Gag (Batonick et al., 2005). Amino acid
residues Y132 andV135 in HIV-1Gag polyprotein are important
for interacting with AP-2 (Batonick et al., 2005); therefore, we
prepared VSVG-pseudotyped mutant viruses possessing Gag
but lacking the AP-2 binding site, HIV-1gagY132A/VSVG
and HIV-1gagV135A/VSVG, and examined the replication le-
vel of those mutant viruses in cells transfected with siRNA
against AP2α. Since HIV-1gagY132A/VSVG had no infectivity
(data not shown), we used HIV-1gagV135A/VSVG in the fol-
lowing experiments. First, we compared the infectivity of HIV-
1gagV135A/VSVG with that of wild-type virus, HIV-1/VSVG.It can be expected that HIV-1gagV135A/VSVG will show
higher infectivity if the interaction between Gag and AP-2 is
required for the inhibitory role of AP2α in HIV-1 replication in
the early stage of the viral life cycle; however, the results showed
that the infectivity of HIV-1gagV135A/VSVG was rather
significantly lower than that of wild-type HIV-1 (Fig. 6A).
Next, we examined the replication of HIV-1gagV135A/VSVG
in J111 cells transfected with siRNA against AP2α. The results
showed that cell transfection with siRNA against AP2α sig-
nificantly enhanced the replication of HIV-1gagV135A/VSVG
as well as wild-type virus (Fig. 6B). These results suggest that
the interaction between HIV-1 Gag V135 and AP-2 is dispen-
sable for the inhibitory role of AP2α on HIV-1 replication in the
early stage of the viral life cycle.
A subpopulation of AP2α is not only localized in the cytoplasm
but is also co-localized with proteins that play roles in the
perinuclear region
On one hand, AP2α has been found to play a role in the
clathrin-dependent endocytosis mechanism at the plasma mem-
brane (Connor and Schmid, 2003; Nakatsu and Ohno, 2003;
176 Y. Kitagawa et al. / Virology 373 (2008) 171–180Robinson, 2004). On the other hand, our results suggest that
AP2α regulates HIV-1 replication in the process of nuclear trans-
location of viral DNA (Fig. 5), implying that AP2α regulates
HIV-1 replication in the cytoplasmic, perinuclear or nuclear re-
gions; therefore, we examined the localization of AP2α by con-
focal fluorescence microscopy. First, we single-stained cells with
the antibody for AP2α, and found that a part of AP2α seemed to
be localized in the cytoplasm aswell as around the nuclear region,
although the majority of AP2α was detected at the plasma mem-
brane (data not shown). The fluorescence signal of AP2α was
dramatically decreased after transfecting J111 cells with siRNA
against AP2α (Supplementary Fig. S3), indicating that AP2αwas
specifically immunostained. Therefore, we then double-stained
cells with antibodies for AP2α and for the protein functioning
in the perinuclear region. The results showed that a subpopulation
of AP2α was partly co-localized with nuclear structural protein,
lamin B (Fig. 7, panels A–D), nuclear transport receptor, importin
β (Fig. 7, panels I–L) and nuclear pore component, Nup153
(Fig. 7, panelsM–P). In contrast, the co-localization of AP2α and
importin α was not clearly observed (Fig. 7, panels E–H). These
results suggest that a subpopulation of AP2α is localized not only
in the cytoplasm, but also in the perinuclear region, and possibly
regulates HIV-1 replication in the process of nuclear translocation
of HIV-1 DNA.
Discussion
In this study, we found a novel inhibitory function of AP2α
in HIV-1 replication in the process of nuclear translocation of
viral DNA.
siRNA induces the RNAi-mediated specific suppression of
target genes in eukaryotic cells (Elbashir et al., 2001). Previously,
we studied the level of HIV-1 replication in cells transfectedwith a
series of siRNAs directed against cellular genes, and found that the
early stage ofHIV-1 replicationwas significantly enhanced in cells
transfected with siRNA against AP2α (Kameoka et al., 2007). In
this study, we further studied the mechanism of how AP2α
regulates HIV-1 replication. AP2α is a major component of AP-2,
and is involved in clathrin-dependent endocytosis as well as the
trafficking ofmolecules from the plasmamembrane to endosomes
(Connor and Schmid, 2003; Nakatsu and Ohno, 2003; Robinson,
2004). AP-2 is therefore involved in HIV-1 Nef-dependent down-
regulation of the CD4 molecule (Chaudhuri et al., 2007; Jin et al.,
2005; Rose et al., 2005). In addition, AP-2 plays a role in the
internalization of HIV-1 Gag (Batonick et al., 2005) and Env
(Boge et al., 1998), eventually leading to the inhibition of virion
formation and the release of virion from infected cells.
Our results show that siRNA against AP2α significantly
enhanced HIV-1 replication in the early phase of the viral life
cycle (Fig. 1), suggesting that AP2α negatively regulates viral
replication under normal cell culture conditions. First, we con-
sidered that AP2α might play a suppressive role in HIV-1 repli-
cation as the functional molecule involved in the clathrin-
dependent endocytosis mechanism; however, siRNA against
clathrin, which inhibits clathrin-dependent endocytosis (Motley
et al., 2003), did not up-regulate HIV-1 replication, in contrast to
siRNAs against AP2α (Fig. 1B). In addition, the early stages ofHIV-1 replication, including viral adsorption, viral entry and RT,
were not enhanced by the transfection of cells with siRNA
against AP2α (Figs. 3 and 4). In stark contrast, the levels of
nuclear viral DNA and integrated proviral DNA were signifi-
cantly up-regulated by transfecting cells with siRNA against
AP2α (Fig. 5). These results suggest that AP2α regulates HIV-1
replication independently of its role in the clathrin-dependent
endocytosis mechanism in the plasma membrane.
AP-2 is known to interact with HIV-1 Gag and to play a role
in the late phase of HIV-1 replication (Batonick et al., 2005). We
examined whether this interaction is required to regulate viral
replication by AP2α. Our studies using the mutant virus pos-
sessing Gag lacking the AP-2 binding site revealed that the
interaction between Gag and AP-2 was dispensable for the
regulatory function of AP2α for HIV-1 replication (Fig. 6).
Thus, it is significant that AP2α regulates HIV-1 replication in
the early stage of the viral life cycle by means of a different
mechanism from the functions known to regulate HIV-1 repli-
cation in the late phase of the viral life cycle.
siRNA against AP2α markedly enhanced the nuclear trans-
location as well as the integration of HIV-1 DNA (Fig. 5),
whereas a subpopulation of AP2αwas localized in the cytoplasm
and the perinuclear region (Fig. 7). Considering these results,
AP2α presumably plays a role in suppressing viral nuclear trans-
location in the cytoplasm or the perinuclear region, although the
detailed mechanism underlying this phenomenon is not under-
stood. One possibility is that AP2α suppresses viral nuclear
translocation through the interaction with viral or cellular protein
(s) associated with intracellular reverse transcription complex
(RTC) or preintegration complex (PIC). Viral proteins, Gag ma-
trix protein (MA), Vpr and integrase, are associated with HIV-1
RTC or PIC, and play roles for the nuclear transport of viral
genome (Bouyac-Bertoia et al., 2001; Bukrinsky et al., 1993;
Bukrinsky, 2004; Gallay et al., 1997; Heinzinger et al., 1994; von
Schwedler et al., 1994). It may be conceivable that AP2α pos-
sibly regulates the function of these nucleophilic viral proteins.
Another possibility is that AP2α interactswith the cellular protein
(s) that plays a role in the process of the nucleocytoplasmic
transport of viral components through nuclear pores, and regu-
lates its function. Indeed, our results show that a subpopulation of
AP2α was co-localized with Nup153 and importin β (Fig. 7),
which are involved in nuclear import of HIV-1 DNA (Bukrinsky,
2004; Gallay et al., 1996, 1997; Popov et al., 1998a,b; Vara-
darajan et al., 2005, Vodicka et al., 1998), implying that AP2α is
involved in the regulation of cellular nuclear import mechanism.
Studies on these possibilities are on going in order to elucidate the
detailed mechanism(s) of how AP2α regulates HIV-1 replication
in the process of nuclear translocation of viral genome.
Materials and methods
siRNA
Two siRNAs directed against AP2α, AP2α siRNA1 (target
sequence: 5′-GGUACCGUGUGCUACAGAU-3′) and AP2α
siRNA2 (siRNA ID: 5397), were purchased from RNAi Co.
(Tokyo, Japan) and Ambion (Austin, Tex.), respectively. AP2α
177Y. Kitagawa et al. / Virology 373 (2008) 171–180siRNA1 is equivalent to the siRNA against AP2α included in
siRNA mini-library (Kameoka et al., 2007). In addition,
the third siRNA against AP2α (AP2α siRNA3, target sequence:
5′-AAGUGGAUGCCUUUCGGGUCA-3′) and siRNA against
clathrin (target sequence: 5′-UAAUCCAAUUCGAAGAC-
CAAU-3′) (Motley et al., 2003) were prepared using a
Silencer™ siRNA Construction kit (Ambion), according to the
manufacturer's instructions. As negative controls, siRNA against
FLJ10847 (siRNA ID: 140539) and control (non-silencing)
siRNAwere purchased from Ambion.
Cells
293T, MAGIC-5A [CCR5-expressing MAGI (HeLa-CD4-
LTR-β-gal)] (Hachiya et al., 2001; Mochizuki et al., 1999) and
J111 cells were maintained in Dulbecco's modified Eagle's
medium (Nacalai Tesque, Inc., Kyoto, Japan) supplemented with
10% heat-inactivated fetal calf serum (FCS) (complete medium).
It is noteworthy that J111 cells (JCRB0073, Lot # 030395; Japan
Health Sciences Foundation, Tokyo, Japan) were originally des-
cribed as a human acute monocytic leukemia, but many data
show this is a subline of HeLa cells (Lavappa, 1978).
siRNA transfection
The cells were transfected with siRNA using HiPerfect trans-
fection reagent (Qiagen, Tokyo, Japan). Briefly, the cells (2–
3×104 cells/500 μl) were seeded in complete medium in a 24-
well plate at 24 h prior to siRNA transfection. The siRNA was
mixed with the transfection reagent to form the RNA/reagent
complex. The cells were then transfected with siRNA (final
25 nM), according to the manufacturer's protocol.
Viral constructs
The pNL4-3 (Adachi et al., 1986)-based, luciferase reporter
viral construct containing the unique recognition sites for BspEI
and NotI at the N- and C-terminus, respectively, of the env gene,
pNL-Luc-envCT [denoted as pNL-envCT in the reference (Kino-
moto et al., 2005b)], was used as X4HIV-1 (HIV-1/X4). R5 HIV-
1 (HIV-1/R5), pNL-Luc-BaLenv, was constructed by replacing
the env gene of pNL-Luc-envCT with the corresponding gene
fragment of pBa-L (GenBank accession no. AB253432), as
follows. Briefly, the env gene of pBa-L was amplified using
PfuUltra™ Hotstart DNA Polymerase (Stratagen) and the pri-
mers, 5′-TGCtccggaAATGAGAGTGAAGGAGA-3′ and 5′-
TGCgcggccgcTTATAGCAAAATCCTTTCC-3′. Lowercase let-
ters indicate the recognition sites for BspE1 (tccgga) and NotI
(gcggccgc). After digestion of the PCR product with BspEI and
NotI, the env gene fragment of pBa-L was introduced into
pNL-Luc-envCT. The luciferase reporter viral construct, pNL-
Luc-gagpolCT, containing the unique recognition site for PvuI,
ClaI and XbaI at the N-terminus of viral protease, reverse tran-
scriptase and integrase gene, respectively, and for BlpI at the C-
terminus of integrase gene, was constructed based on pNL-Luc-
ProCT (Kinomoto et al., 2005a) by site-directed mutagenesis. In
addition, its Env-deficient derivative, pNL-Luc-E−-gagpolCT,was constructed by introducing a frameshift mutation at the NdeI
recognition site in the env gene. pNL-Luc-E−-gagY132A and
pNL-Luc-E−-gagV135A were constructed using pNL-Luc-E−-
gagpolCT by site-directed mutagenesis. Env-deficient viral
constructs, pNL-Luc-E−-gagY132A, pNL-Luc-E−-gagV135A
and pNL-Luc-E−R+ (Chen et al., 1994; Connor et al., 1995), as
well as VSVG-expression vector, pHIT/G (Fouchier et al., 1997),
were used to prepare the VSVG-pseudotyped reporter HIV-1
(HIV-1gagY132A/VSVG, HIV-1gagV135A/VSVG and HIV-1/
VSVG, respectively). Viral supernatants were prepared by trans-
fecting 293T cells with proviral constructs using FuGENE 6
transfection reagent (Roche), essentially as described (Kameoka
et al., 2004). Forty-eight hours after transfection, supernatants
were filtered though a 0.45-μm-pore-size filter and stored as
aliquots at −85 °C. The viral titer was determined by measuring
the concentration of HIV-1 Gag p24 antigen in viral supernatants
by enzyme-linked immunosorbent assay (ELISA) (ZeptoMetrix
Corp., Buffalo, NY).
Viral infectivity assay
Cells were incubated with viral supernatant (40 ng of p24)
for 1 h at 37 °C. The viral supernatant was then replaced with
complete medium, and the cells were cultured for 24 h at 37 °C.
They were then lysed in 100 μl of reporter lysis buffer (Passive
Lysis Buffer, Promega), the supernatant (lysate) was clarified at
15,000 rpm for 5 min at 4 °C, and luciferase activity in 10 μl of
lysate was determined using the luciferase assay system
(Promega). Luciferase activity was measured using Lumat LB
9507 (Berthold Japan, Tokyo, Japan).
Viral adsorption assay
The cells were incubated with viral supernatant (40 ng of
p24) for 1 h at 4 °C. After thoroughly washing with cold
phosphate-buffered saline (PBS), the cells were lysed in 80 μl of
p24 ELISA lysis buffer (supplemented with an ELISA kit to
detect p24 antigen). The level of viral adsorption to cells was
determined by measuring the concentration of HIV-1 Gag p24
antigen in the cell lysate by ELISA, as described above. Env-
deficient HIV-1 virion was prepared by transfecting 293T cells
with pNL-Luc-E−R+, and was used as a negative control.
Viral entry assay
The cells were incubated with viral supernatants (40 ng of p24)
for 1 h at 4 °C. After thoroughly washing with cold PBS, the cells
were incubated in complete medium for 1 h at 37 °C. They were
then trypsinized to remove viruses attached to the cell surface.
The cell lysate was then prepared and the amount of p24 antigen
in the samples wasmeasured by ELISA, as described above. Env-
deficient HIV-1 virion was used as a negative control.
Semi-quantification of reverse transcribed viral DNA
The cells were infected with HIV-1 (40 ng of p24). Prior to
infection, the viral supernatant was treated with 1000 U/ml of
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was then extracted at various times after infection, using a
QIAamp DNA blood mini kit (Qiagen). Real-time PCR was
carried out for the semi-quantification of HIV-1 DNA. Briefly,
cellular DNA (50–150 ng) was mixed with a 12.5 μl reaction
mixture containing 2× TaqMan universal PCR master mix (Ap-
plied Biosystems), HIV-1-specific primers (300 nM each) and the
TaqMan probe. HIV-1 specific primers, RS; 5′-AACTAGG-
GAACCCACTGCTTAAG-3′ [nucleotide (nt) 500 to 522 of
pNL4-3], U5AS; 5′-CGCCACTGCTAGAGATTTTCCAC-3′ (nt
640 to 618), U5S; 5′-CAGACCCTTTTAGTCAGTGTGGAA-3′
(nt 600 to 623) and 5NCAS; 5′-CTCTGGCTTTACTTTCG-
CTTTCA-3′ (nt 677 to 655), and the TaqMan probes, RU5 probe;
5′-FAM-ACACTACTTGAAGCACTCAAGGCAAGCTTT-
TAMRA-3′ (nt 9634 to 9605; corresponding to nt 559 to 530) and
U55NC probe; 5′-FAM-TCTCTAGCAGTGGCGCCCGAACA-
TAMRA-3′ (nt 626 to 648), were used. Primer pair RS–U5AS
and RU5 probe were designed to detect the earliest RT product.
Primer pair U5S–5NCAS and U55NC probe were expected to
detect only the late RT product synthesized after the second
template switch. Real-time PCR was carried out using ABI
PRISM 7900HT (Applied Biosystems), according to the manu-
facturer's instructions. To monitor the efficiency of DNA extrac-
tion, β-actin DNA was also amplified using TaqMan β-actin
control reagents (Applied Biosystems). The plasmid, pNL-Luc-
E−R+, was serially 10-fold diluted and subjected to real-time PCR
to make a standard plot, and the copy number of HIV-1 DNAwas
calculated using SDS software version 2.2.2 (Applied Bio-
systems). The level of HIV-1 DNAwas standardized by dividing
the copy number of HIV-1 DNA by that of β-actin to compensate
for variations in the quantity or quality of DNA samples, and the
results are shown as the copy number of HIV-1 DNA per cell.
Evaluation of the level of viral nuclear translocation
The level of viral nuclear translocation was evaluated by
measuring the level of the 2-LTR circular form of viral DNA
using inverted PCR, essentially as described previously (Cara
et al., 2002; Chang et al., 2005). Real-time nested PCR was
carried out as follows. Cellular DNA was subjected to the first
PCR using Blend Taqplus (Toyobo, Osaka, Japan) and a pair of
primers, U3S; 5′-GAGCCCTCAGATGCTGCATATAAG-3′ (nt
9484 to 9507) and U3AS; 5′-GCAGCTCTCGGGCCATGT-
GACG-3′ (nt 306 to 285). Then, a 1-μl aliquot of first PCR
product was mixed with a 15-μl reaction mixture containing 2×
TaqMan universal PCR master mix (Applied Biosystems), RS;
5′-AACTAGGGAACCCACTGCTTAAG-3′ (nt 9575 to 9597)
(300 nM) and U3AS2; 5′-TCCACAGATCAAGGATATCT-
TGTC-3′ (nt 51 to 28) (300 nM) and RU5 probe; 5′-FAM-
ACACTACTTGAAGCACTCAAGGCAAGCTTT-TAMRA-
3′ (nt 9634 to 9605) (200 nM). Real-time PCR was carried out
as described above. The PCR product (2-LTR fragment), ampli-
fied by using the primer pair RS-U3AS2, was cloned in pT7Blue
T-vector (Novagen). The plasmid containing the 2-LTR frag-
ment was then serially diluted and subjected to real-time PCR to
make a standard plot, and the amount of the 2-LTR circular form
of HIV-1 DNA was estimated. The level of HIV-1 DNA wasstandardized by dividing the copy number of HIV-1DNA by that
ofβ-actin, and the results are shown as the relative amount of the
2-LTR form of HIV-1 DNA.
Evaluation of the level of viral integration
Real-time nested PCR for the semi-quantification of integrated
HIV-1 DNA was carried out using the primer specific for Alu
DNA repeats, which are randomly distributed, roughly 5000 bp
apart, in the chromosome (Jelinek and Schmid, 1982), combined
with primers for the HIV-1 genome, essentially as described
(Kameoka et al., 2005). Briefly, cellular DNAwas subjected to the
first PCR using Blend Taqplus (Toyobo) and a pair of primers,
U3S; 5′-GAGCCCTCAGATGCTGCATATAAG-3′ (nt 9484 to
9507) and Alu primer; 5′-TCCCAGCTACTCGGGAGGC-
TGAGG-3′. Then, a 1-μl aliquot of first PCR product was
mixed with a 12.5-μl reaction mixture containing 2× TaqMan
universal PCR master mix (Applied Biosystems), RS; 5′-AAC-
TAGGGAACCCACTGCTTAAG-3′ (nt 500 to 522) (300 nM),
U5AS; 5′-CGCCACTGCTAGAGATTTTCCAC-3′ (nt 640 to
618) (300 nM) and RU5 probe; 5′-FAM-ACACTACTTGAAG-
CACTCAAGGCAAGCTTT-TAMRA-3′ (nt 9634 to 9605;
corresponding to nt 559 to 530) (200 nM). Real-time PCR was
carried out, as described above. Serially diluted plasmid, pNL-
Luc-E−R+, was subjected to real-time PCR to make a standard
plot, and the amount of HIV-1 DNAwas estimated, as described
above. The level of HIV-1 DNAwas standardized by dividing the
copy number of HIV-1 DNA by that ofβ-actin, and the results are
shown as the relative amount of HIV-1 proviral DNA.
Immunoblotting
Cells were lysed in sample buffer [62.5 mM Tris–HCl,
pH 6.8, 2% sodium dodecylsulfate (SDS), 10% glycerol, 5%
2-mercaptoethanol and 0.003% bromophenol blue]. Samples
were then separated by SDS–polyacrylamide gel electrophor-
esis (SDS–PAGE), and transferred to a polyvinylidene fluo-
ride (PVDF) membrane. After blocking with 5% non-fat milk
in PBS, the blots were immunostained with anti-AP2α (adap-
tin α) monoclonal antibody (#610502; BD Biosciences, San
Jose, CA), anti-clathrin heavy chain monoclonal antibody
(#61500; BD Biosciences) or anti-α-tubulin monoclonal an-
tibody (#T5168; Sigma, Saint Louis, MO). After incubation of
the samples with peroxidase-labeled secondary antibodies, the
immuno-complex was visualized using ECL Western blotting
detection reagents (Amersham Pharmacia Biotech).
Confocal fluorescence microscopy
For immunofluorescence analysis, J111 cells were seeded in
a Lab-Tek™ II chamber slide (Nalge Nunc International).
Twenty-four hours later, the cells were fixed with 4% para-
formaldehyde for 15 min at 4 °C, and then permeabilized with
0.1% Triton X-100 in PBS for 5 min. The samples were then
immunostained with an antibody for AP2α (#610502; BD
Biosciences), followed by an Alexa 488-conjugated secondary
antibody. For double staining, the samples were further stained
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ogy, Santa Cruz, CA), importin α (sc-6917, Santa Cruz Bio-
technology), importin β (sc-1863, Santa Cruz Biotechnology)
or Nup153 (#BP4506; Acris Antibody GmbH, Hiddenhausen,
Germany), followed by Alexa 594- or Cy3-conjugated secon-
dary antibody. Fluorescence images of the cells were observed
using a laser-scanning confocal microscope, Fluoview FV1000
(Olympus, Tokyo, Japan) with a 60× oil immersion objective
(NA1.35). Fluorochromes were excited using an argon laser for
Alexa 488, and a helium/neon laser for Alexa 594 and Cy3.
Image analysis was carried out using standard functions of the
FV10-ASW viewer software version 1.6 (Olympus).
Evaluation of HIV-1 Nef-dependent CD4 down-regulation
The nef gene of pNL4-3 was cloned in pcDNA3.1 (Invitrogen)
to generate a Nef-expression vector, pcDNA-Nef. MAGIC5A
cells were transfected with clathrin siRNA, AP2α siRNA1 or
control (non-silencing) siRNA. Forty-eight hours after siRNA
transfection, cells were further transfected with pcDNA-Nef or
pcDNA3.1 (2 μg) using the Nucleofector-II device (Amaxa
Biosystems,Nattermannallee 1,Germany;Cell LineNucleofector
Kit R and program I-13). Forty-eight hours after DNA trans-
fection, cells were harvested and immunostained with phycoer-
ythrin (PE)-conjugated anti-CD4monoclonal antibody (#347327,
BDBiosciences). As a negative control, cells were incubated with
PE-conjugated mouse IgG2b (#33805X, BD Biosciences). Then,
samples were subjected to flow cytometry using FACSCalibur
(BD Biosciences) with CellQuest software (BD Biosciences).
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